Cutera (NASDAQ:CUTR) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Cutera (NASDAQ:CUTR) in a report issued on Sunday. The firm set a “sell” rating on the medical device company’s stock.

Cutera Stock Down 10.5 %

NASDAQ CUTR opened at $0.32 on Friday. The firm has a market cap of $6.51 million, a P/E ratio of -0.05 and a beta of 1.32. Cutera has a 52-week low of $0.28 and a 52-week high of $3.00. The business’s 50-day moving average price is $0.43 and its 200 day moving average price is $0.54.

Institutional Investors Weigh In On Cutera

An institutional investor recently bought a new position in Cutera stock. Sculptor Capital LP purchased a new stake in shares of Cutera, Inc. (NASDAQ:CUTR) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 166,000 shares of the medical device company’s stock, valued at approximately $59,000. Sculptor Capital LP owned 0.82% of Cutera at the end of the most recent quarter. Hedge funds and other institutional investors own 90.70% of the company’s stock.

About Cutera

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.